Search

Displaying results 1181 - 1190 of 7283 in total
  1. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses.

  2. Drug

    Senazodan

    go.drugbank.com/drugs/DB19879
    Experimental

    Senazodan has a monoisotopic molecular weight of 266.12 Da. … Senazodan is a small molecule drug. The usage of the INN stem '-dan' in the name indicates that Senazodan is a cardiac stimulant, pimobendan derivative.

  3. Drug

    Adibendan

    go.drugbank.com/drugs/DB20623
    Experimental

    Adibendan has a monoisotopic molecular weight of 278.12 Da. … Adibendan is a small molecule drug. The usage of the INN stem '-dan' in the name indicates that Adibendan is a cardiac stimulant, pimobendan derivative.

  4. Drug

    Firuglipel

    go.drugbank.com/drugs/DB19506
    Investigational

    Firuglipel has a monoisotopic molecular weight of 467.19 Da. … Firuglipel is a small molecule drug. Firuglipel is under investigation in clinical trial NCT02647320 (12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin).

  5. Drug

    Imdatifan

    go.drugbank.com/drugs/DB21643
    Experimental

    Imdatifan has a monoisotopic molecular weight of 385.05 Da. … Imdatifan is a small molecule drug. The usage of the INN stem '-tifan' in the name indicates that Imdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor.

  6. Drug

    Piretanide

    go.drugbank.com/drugs/DB02925
    Approved

    Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in

    Mixtures: RAMIPRIL PIRETA 1A PHA 5/6, RAMIPRIL PIRETA 1A PHA 5/6Products: PIRETANID 3 1A PHARMA, PIRETANID 6 1A PHARMA
  7. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. … FDA approved on December 21, 2012.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. … Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.

  9. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    [A190528] Ferric derisomaltose is a form of iron used in the treatment of iron deficiency. This drug is a complex of iron (III) hydroxide and derisomaltose. … Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020.

  10. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. … This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth.